Scientists at the Norwegian University of Science and Technology have uncovered that Janus kinase inhibitors (JAKs), commonly used to treat inflammatory conditions, might unintentionally help viruses like COVID-19 and influenza spread by dampening key immune responses.
- JAK inhibitors reduce immune signaling that protects cells from viruses
- Viruses like SARS-CoV-2 and influenza may spread more easily under these drugs
- Careful prescription advised during viral outbreaks or latent infections
What happened
Researchers at NTNU discovered that JAK inhibitors, a class of widely used anti-inflammatory drugs, can suppress vital immune pathways that help the body resist viral infections. Using advanced lab techniques and organoid models from lung, eye, and brain tissue, they demonstrated that these medications reduce the activity of genes responsible for antiviral defense.
This weakened immune signaling allows viruses such as Rift Valley fever virus, influenza A, adenovirus, and SARS-CoV-2 to infect healthy cells more easily and spread within the body. The findings were detailed in a recent publication that highlights the unintended consequences of these drugs beyond their inflammation-fighting benefits.
Why it feels good
Despite the potential risks, JAK inhibitors remain an important treatment for millions suffering from autoimmune and inflammatory disorders, such as rheumatoid arthritis, where controlling inflammation can vastly improve quality of life. Understanding their effects on viral defense helps patients and healthcare providers make more informed decisions.
This research also opens doors for scientists to explore how these immune-modulating drugs might be used in controlled ways to improve vaccine development or antiviral testing under laboratory conditions, turning a potential vulnerability into a scientific advantage.
What to enjoy or watch next
As awareness grows around the immune effects of JAK inhibitors, patients and doctors can anticipate updated guidelines to balance managing inflammation while reducing infection risks—especially during flu seasons or COVID-19 surges. Monitoring ongoing research will be key to safer, more effective use of these medications.
For anyone interested in the intersection of immune health and drug development, watching how scientists leverage organoid technology and gene expression analysis will be fascinating. These advances continue to improve our understanding of complex drug-virus interactions and may lead to breakthroughs in treating infectious diseases alongside chronic inflammatory conditions.